Meeting
2021 ASCO Annual Meeting
Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.
Authors
Suzette Girgis
Janssen R&D, Spring House, PA
Suzette Girgis , Shun Xin Wang Lin , Kodandaram Pillarisetti , Raluca Verona , Diego Vieyra , Tineke Casneuf , Damien Fink , Xin Miao , Yang Chen , Tara Stephenson , Arnob Banerjee , Brandi Hilder , Jeffery Scott Russell , Jennifer Smit , Jenna D. Goldberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03145181 and NCT03399799
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8047)
DOI
10.1200/JCO.2021.39.15_suppl.8047
Abstract #
8047
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.
First Author: William Bensinger
Poster
2024 ASCO Annual Meeting
Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.
First Author: Allison Graeter
Poster
2024 ASCO Annual Meeting
Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.
First Author: Radhika Bansal
Poster
2023 ASCO Annual Meeting
Population pharmacokinetic-pharmacodynamic model of nirogacestat effects on B-cell maturation antigen in healthy subjects.
First Author: Todd Shearer